WO2010007085A3 - Use of gcn5 inhibitors in medicine - Google Patents

Use of gcn5 inhibitors in medicine Download PDF

Info

Publication number
WO2010007085A3
WO2010007085A3 PCT/EP2009/059036 EP2009059036W WO2010007085A3 WO 2010007085 A3 WO2010007085 A3 WO 2010007085A3 EP 2009059036 W EP2009059036 W EP 2009059036W WO 2010007085 A3 WO2010007085 A3 WO 2010007085A3
Authority
WO
WIPO (PCT)
Prior art keywords
gcn5
inhibitors
medicine
disease
metabolic
Prior art date
Application number
PCT/EP2009/059036
Other languages
French (fr)
Other versions
WO2010007085A2 (en
Inventor
Carina Cristina Sanchez
Susan C. Stevenson
Zhidan Wu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2010007085A2 publication Critical patent/WO2010007085A2/en
Publication of WO2010007085A3 publication Critical patent/WO2010007085A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Use of a GCN5 inhibitor or pharmaceutically acceptable salt thereof, for the prevention, delay of progression or the treatment of diabetes, insulin resistance, metabolic disease/metabolic syndrome, dyslipidemia, obesity, overweight, neurodegenerative diseases heart failure, muscle disease, or improvement of exercise endurance capacity.
PCT/EP2009/059036 2008-07-17 2009-07-15 Use of organic compounds WO2010007085A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8157508P 2008-07-17 2008-07-17
US61/081,575 2008-07-17

Publications (2)

Publication Number Publication Date
WO2010007085A2 WO2010007085A2 (en) 2010-01-21
WO2010007085A3 true WO2010007085A3 (en) 2010-03-25

Family

ID=41226708

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/059036 WO2010007085A2 (en) 2008-07-17 2009-07-15 Use of organic compounds

Country Status (1)

Country Link
WO (1) WO2010007085A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3055548B1 (en) * 2016-09-05 2018-09-28 Metabrain Research USE OF METABOLITES OF TRYPTOPHAN IN THE TREATMENT OF MUSCLE ATROPHY
KR102699674B1 (en) * 2016-12-12 2024-08-26 건국대학교 글로컬산학협력단 Biomarker GCN5 for diagnosing neurodegenerative disease and use thereof
CN108864015A (en) * 2018-08-28 2018-11-23 青海大学 It is a kind of to have effects that treat the compound and pharmaceutical composition of neurodegenerative disease
GB2601520A (en) * 2020-12-02 2022-06-08 Chemestmed Ltd Method of survival and protection of neurons by inhibitors of RNA m6A demethylases FTO and ALKBH5

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068944A2 (en) * 2002-02-13 2003-08-21 Dana-Farber Cancer Institute, Inc. METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
WO2006026785A2 (en) * 2004-09-03 2006-03-09 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR MODULATING PGC-1α TO TREAT NEUROLOGICAL DISEASES AND DISORDERS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068944A2 (en) * 2002-02-13 2003-08-21 Dana-Farber Cancer Institute, Inc. METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
WO2006026785A2 (en) * 2004-09-03 2006-03-09 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR MODULATING PGC-1α TO TREAT NEUROLOGICAL DISEASES AND DISORDERS

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
A. MAI ET AL: "Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties", JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, no. 23, 2006, pages 6897 - 6907, XP002563930 *
C. LERIN ET AL: "GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha", CELL METABOLISM, vol. 3, no. 6, June 2006 (2006-06-01), pages 429 - 438, XP002563928 *
HANDSCHIN ET AL: "The biology of PGC-1alpha and its therapeutic potential", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 30, no. 6, 1 June 2008 (2008-06-01), pages 322 - 329, XP026157972, ISSN: 0165-6147, [retrieved on 20090514] *
M. BIEL ET AL.: "Design, synthesis and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase GCN5", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 43, no. 30, 2004, pages 3974 - 3976, XP002563931 *
POUX A N ET AL: "Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 22, 29 October 2002 (2002-10-29), pages 14065 - 14070, XP003002310, ISSN: 0027-8424 *
Y. LIU, M. MONTMINY: "CAT in the HAT: Catabolic inhibition by the histone acetyltransferase GCN5", CELL METABOLISM, vol. 3, no. 6, June 2006 (2006-06-01), pages 387 - 388, XP002563929 *

Also Published As

Publication number Publication date
WO2010007085A2 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
WO2007131005A3 (en) Use of organic compounds
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
WO2010049678A3 (en) Treatment of energy utilization diseases
EA033415B1 (en) Methods for treating obesity, use of dpp-4 inhibitor in these methods and method for treating patients suffering from type 2 diabetes mellitus
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
WO2009055331A3 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
WO2012156317A3 (en) Intranasal pharmaceutical dosage forms comprising naloxone
WO2008096775A1 (en) Therapeutic agent for pain disease
ZA200805716B (en) Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
MX2009011357A (en) Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof.
WO2007149797A3 (en) Use of organic compounds
WO2009127974A3 (en) Pharmaceutical formulation for treating cardiovascular disease
MX2012006734A (en) Ppar-sparing thiazolidinediones and combinations for the treatment of obesity and other metabolic diseases.
IL226386A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obestiy or prediabetes
WO2012019188A3 (en) Methods and compositions for the inhibition of fructokinase
WO2010007085A3 (en) Use of gcn5 inhibitors in medicine
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
WO2005039578A3 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
WO2012142575A3 (en) Monomeric trioxane amide sulfur compounds
WO2009013010A3 (en) 5ht6-ligands such as sulfonamide derivatives in drug- induced weight-gain
WO2010044581A2 (en) N1-benzo[1,3]dioxol-5-ylmethyl-n2-substituted biguanide derivative, preparation method thereof, and pharmaceutical composition containing same
EP1769793A4 (en) Therapeutic or preventive drug for diabetes, obesity, or arteriosclerosis
WO2007070564A3 (en) Methods of treating obesity using enterostatin
WO2008120617A1 (en) Pharmaceutical composition for prevention of progress of intestinal constriction associated with crohn's disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09780609

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09780609

Country of ref document: EP

Kind code of ref document: A2